Cardiovascular safety risks associated with gout treatments

References

• Fathallah-Shaykh SA, Cramer MT. Uric acid and the kidney. Pediatr Nephrol. 2014;29:999–1008.
   PubMed Web of Science ®Google Scholar
• Wu XW, Muzny DM, Lee CC, et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992;34:78–84.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a new staging system? Ann Rheum Dis. 2014;73:1598–1600.
   PubMed Web of Science ®Google Scholar
• Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, hyperuricaemia and crystal-associated disease network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019;78:1592–1600.
   PubMed Web of Science ®Google Scholar
• Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012;3:764.
   PubMed Web of Science ®Google Scholar
• Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–241.
   PubMed Web of Science ®Google Scholar
• Desai J, Steiger S, Anders H-J. Molecular pathophysiology of Gout. Trends Mol Med. 2017;23:756–768.
   PubMed Web of Science ®Google Scholar
• Kanbay M, Segal M, Afsar B, et al. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013;99:759–766.
   PubMed Web of Science ®Google Scholar
• Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008;52:818–827.
   PubMed Web of Science ®Google Scholar
• Selby JV, Friedman GD, Quesenberry CP Jr. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol. 1990;131:1017–1027.
   PubMed Web of Science ®Google Scholar
• Cheng Y-B LY. Hyperuricemia. Hypertension. 2018;71:66–67.
   PubMedGoogle Scholar
• Kuwabara M, Kanbay M, Hisatome I. Uric acid and hypertension because of arterial stiffness. Hypertension. 2018;72:582–584.
   PubMed Web of Science ®Google Scholar
• Mallat SG, Al Kattar S, Tanios BY, et al. Hyperuricemia, hypertension, and chronic kidney disease: an emerging association. Curr Hypertens Rep. 2016;18:74.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Kawaguchi A, Tomiyama H, et al. Cross-sectional and longitudinal associations between serum uric acid and endothelial function in subjects with treated hypertension. Int J Cardiol. 2018;272:308–313.
   PubMed Web of Science ®Google Scholar
• Buzas R, Tautu OF, Dorobantu M, et al. Serum uric acid and arterial hypertension-data from Sephar III survey. PLoS One. 2018;13:e0199865.
   PubMed Web of Science ®Google Scholar
• Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012;19:358–371.
   PubMed Web of Science ®Google Scholar
• Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8(Suppl 1):S1–S.
   PubMed Web of Science ®Google Scholar
• Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta. 2018;484:150–163.
   PubMed Web of Science ®Google Scholar
• Kuwabara M, Hisatome I, Niwa K, et al. Uric acid is a strong risk marker for developing hypertension from prehypertension. Hypertension. 2018;71:78–86.
   PubMed Web of Science ®Google Scholar
• Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101–1106.
   PubMed Web of Science ®Google Scholar
• Acevedo A, Benavides J, Chowdhury M, et al. Hyperuricemia and cardiovascular disease in patients with hypertension. Conn Med. 2016;80:85–90.
   PubMedGoogle Scholar
• Cho J, Kim C, Kang DR, et al. Hyperuricemia and uncontrolled hypertension in treated hypertensive patients: K-MetS study. Medicine (Baltimore). 2016;95:e4177.
   PubMed Web of Science ®Google Scholar
• Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63:102–110.
   PubMed Web of Science ®Google Scholar
• Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension: the olivetti heart study. J Hum Hypertens. 1994;8:677–681.
   PubMed Web of Science ®Google Scholar
• Fang J, Alderman MH. Serum uric acid and cardiovascular mortalityThe NHANES I epidemiologic follow-up study, 1971-1992. JAMA. 2000;283:2404–2410.
   PubMed Web of Science ®Google Scholar
• Holme I, Aastveit AH, Hammar N, et al. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417 734 men and women in the apolipoprotein mortality riSk study (AMORIS). J Intern Med. 2009;266:558–570.
   PubMed Web of Science ®Google Scholar
• Borghi C, Rodriguez-Artalejo F, De Backer G, et al. Serum uric acid levels are associated with cardiovascular risk score: A post hoc analysis of the EURIKA study. Int J Cardiol. 2018;253:167–173.
   PubMed Web of Science ®Google Scholar
• Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study. Ann Intern Med. 1999;131:7–13.
   PubMed Web of Science ®Google Scholar
• Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546–2551.
   PubMed Web of Science ®Google Scholar
• Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78:6858–6862.
   PubMed Web of Science ®Google Scholar
• Guzik TJ, West NE, Black E, et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res. 2000;86:E85–90.
   PubMed Web of Science ®Google Scholar
• Spiekermann S, Landmesser U, Dikalov S, et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. 2003;107:1383–1389.
   PubMed Web of Science ®Google Scholar
• Allopurinol approval package Fl.
   Google Scholar
• Jutkowitz E, Choi HK, Pizzi LT, et al. Cost-effectiveness of allopurinol and febuxostat for the management of Gout. Ann Intern Med. 2014;161:617–626.
   PubMed Web of Science ®Google Scholar
• Jordan KM, Cameron JS, Snaith M, et al. British society for rheumatology and British Health Professionals in rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46:1372–1374.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug adminsitratio (FDA). Product information Zyloprim (Allopurinol). 2018. (Updated 2020 Jun 29, Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016084s044lbl.pdf.)
   Google Scholar
• Kok VC, Horng J-T, Chang W-S, et al. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. PLoS One. 2014;9:e99102–e.
   PubMed Web of Science ®Google Scholar
• Kim SC, Schneeweiss S, Choudhry N, et al. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015;128:653.e7-.e16.
   Web of Science ®Google Scholar
• Søltoft Larsen K, Pottegård A, Lindegaard HM, et al. Impact of urate level on cardiovascular risk in allopurinol treated patients. a nested case-control study. PLoS One. 2016;11:e0146172–e.
   PubMed Web of Science ®Google Scholar
• Struthers AD, Donnan PT, Lindsay P, et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart. 2002;87:229–234.
   PubMed Web of Science ®Google Scholar
• Singh JA, Ramachandaran R, Yu S, et al. Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. BMC Cardiovasc Disord. 2017;17:76.
   PubMed Web of Science ®Google Scholar
• Singh JA, Yu S. Allopurinol and the risk of stroke in older adults receiving medicare. BMC Neurol. 2016;16:164.
   PubMed Web of Science ®Google Scholar
• Singh JA, Cleveland J. Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US medicare data. BMC Med. 2017;15:59.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang C, Xu Z, et al. Clinical study on efficacy of allopurinol in patients with acute coronary syndrome and its functional mechanism. Hellenic J Cardiol. 2017;58:360–365.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388–1393.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis. 2015;65:543–549.
   PubMed Web of Science ®Google Scholar
• Erdogan D, Tayyar S, Uysal BA, et al. Effects of allopurinol on coronary microvascular and left ventricular function in patients with idiopathic dilated cardiomyopathy. Can J Cardiol. 2012;28:721–727.
   PubMed Web of Science ®Google Scholar
• Inoue T, Sakai Y, Morooka S, et al. Vasodilatory capacity of coronary resistance vessels in dilated cardiomyopathy. Am Heart J. 1994;127:376–381.
   PubMed Web of Science ®Google Scholar
• Szwejkowski BR, Gandy SJ, Rekhraj S, et al. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J Am Coll Cardiol. 2013;62:2284–2293.
   PubMed Web of Science ®Google Scholar
• Kostka-Jeziorny K, Uruski P, Tykarski A. Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. Blood Press. 2011;20:104–110.
   PubMed Web of Science ®Google Scholar
• Higgins P, Walters MR, Murray HM, et al. Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial. Heart. 2014;100:1085–1092.
   PubMed Web of Science ®Google Scholar
• Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300:924–932.
   PubMed Web of Science ®Google Scholar
• McMullan CJ, Borgi L, Fisher N, et al. Effect of uric acid lowering on renin-angiotensin-system activation and ambulatory BP: a randomized controlled trial. Clin J Am Soc Nephrol. 2017;12:807–816.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug adminsitratio (FDA).ULORIC (febuxostat) tablet for oral use. 2017. (Updated 2020 Jun 29. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021856s011lbl.pdf.)
   Google Scholar
• Ernst ME, Fravel MA. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin Ther. 2009;31:2503–2518.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR Jr., Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–2461.
   PubMed Web of Science ®Google Scholar
• Kang EH, Choi HK, Shin A, et al. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. Rheumatology (Oxford). 2019;58(12):2122–2129.
   Web of Science ®Google Scholar
• Foody J, Turpin RS, Tidwell BA, et al. Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor. Am Health Drug Benefits. 2017;10:393–401.
   PubMed Web of Science ®Google Scholar
• Su CY, Shen LJ, Hsieh SC, et al. Comparing cardiovascular safety of febuxostat and allopurinol in the real world: a population-based cohort study. Mayo Clin Proc. 2019;94:1147–1157.
   PubMed Web of Science ®Google Scholar
• Gunawardhana L, Becker MA, Whelton A, et al. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Res Ther. 2018;20:99.
   PubMed Web of Science ®Google Scholar
• Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients >/=65 years of age. BMC Geriatr. 2012;12:11.
   PubMed Web of Science ®Google Scholar
• Kojima S, Matsui K, Hiramitsu S, et al. Febuxostat for cerebral and cardiorenovascular events prevention study. Eur Heart J. 2019;40:1778–1786.
   PubMed Web of Science ®Google Scholar
• White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with Gout. N Engl J Med. 2018;378:1200–1210.
   PubMed Web of Science ®Google Scholar
• Cardiovascular Safety in Gout: Interpreting Data From the CARES Trial. 2019. (Updated 2020 Jun 24, at https://www.thecardiologyadvisor.com/home/topics/chd/cardiovascular-safety-in-gout-interpreting-data-from-the-cares-trial/.)
   Google Scholar
• FitzGerald JD, Dalbeth N, Mikuls T, et al. American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744–760.
   Web of Science ®Google Scholar
• Jansen T, Janssen M. Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation. Clin Rheumatol. 2019;38:263–265.
   PubMed Web of Science ®Google Scholar
• Voelker R. Another Warning for Febuxostat. JAMA. 2019;321:1245.
   Web of Science ®Google Scholar
• Sezai A, Soma M, Nakata K, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J. 2013;77:2043–2049.
   PubMed Web of Science ®Google Scholar
• Hiramitsu S, Ishiguro Y, Matsuyama H, et al. Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems. Clin Exp Hypertens. 2014;36:433–440.
   PubMed Web of Science ®Google Scholar
• Hays AG, Iantorno M, Schar M, et al. The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo-controlled, double-blind, crossover trial. Am Heart J. 2018;197:85–93.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Zurampic (lesinurad) approved by US FDA for patients with gout. Updated February 24, 2020. Avaialble from: https://www.astrazeneca-us.com/media/press-releases/2015/zurampic-lesinurad-approved-by-us-fda-for-patients-20151222.html
   Google Scholar
• Deeks ED. Lesinurad: A Review in Hyperuricaemia of Gout. Drugs Aging. 2017;34:401–410.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug adminsitratio (FDA).ZURAMPIC®(lesinurad) tablets, for oral use 2015. Updated 2020 Jun 29 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf.)
   Google Scholar
• Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2017;76:811–820.
   PubMed Web of Science ®Google Scholar
• Shen Z, Gillen M, Tieu K, et al. Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study. Drug Des Devel Ther. 2016;10:3509–3517.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheumatol. 2017;69:1903–1913.
   PubMed Web of Science ®Google Scholar
• Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol. 2017;69:203–212.
   PubMed Web of Science ®Google Scholar
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
   Google Scholar
• U.S. Food & Drug adminsitratio (FDA).KRYSTEXXA® (pegloticase). 2012. Updated 2020 Jun 29. Avaialble from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125293s034lbl.pdf.)
   Google Scholar
• Johnson Richard J, Choi Hyon K, Yeo Anthony E, et al. Pegloticase treatment significantly decreases blood pressure in patients with chronic Gout. Hypertension. 2019;74:95–101.
   PubMed Web of Science ®Google Scholar
• Fini MA, Stenmark KR. Pegloticase and lowering blood pressure in refractory gout; is it uric acid or hydrogen peroxide? Eur J Intern Med. 2019;69:e11–e12.
   PubMed Web of Science ®Google Scholar
• Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58:2882–2891.
   PubMed Web of Science ®Google Scholar
• Hershfield MS, Roberts LJ 2nd, Ganson NJ, et al. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci U S A. 2010;107:14351–14356.
   PubMed Web of Science ®Google Scholar
• Sundy JS, Baraf HSB, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic Gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711–720.
   PubMed Web of Science ®Google Scholar
• Slobodnick A, Shah B, Pillinger MH, et al. Colchicine: old and new. Am J Med. 2015;128:461–470.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug adminsitratio (FDA).COLCRYS (colchicine, USP) tablets, for oral use. 2020. Updated 2020 Jun 29. Avaialble from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022352s026lbl.pdf#page=25.)
   Google Scholar
• Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404–410.
   PubMed Web of Science ®Google Scholar
• Deftereos S, Giannopoulos G, Panagopoulou V, et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail. 2014;2:131–137.
   PubMed Web of Science ®Google Scholar
• O’Keefe JH Jr., McCallister BD, Bateman TM, et al. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol. 1992;19:1597–1600.
   PubMed Web of Science ®Google Scholar
• Tardif J-C, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–2505.
   PubMed Web of Science ®Google Scholar
• Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–241.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug adminsitratio (FDA).ILARIS® (canakinumab) for injection, for subcutaneous use. 2016. Updated 2020 Jun 29. Avaialble from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125319Orig1s085,086,087Lbl.pdf.)
   Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131.
   PubMed Web of Science ®Google Scholar
• Schlesinger N. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels. Ann Intern Med. 2019;170:737–738.
   PubMed Web of Science ®Google Scholar
• Sehested TSG, Bjerre J, Ku S, et al. Cost-effectiveness of canakinumab for prevention of recurrent cardiovascular events. JAMA Cardiol. 2019;4:128–135.
   PubMed Web of Science ®Google Scholar
• Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout—a systematic review. Rheumatology. 2006;45:1422–1431.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug adminsitratio (FDA). FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. Updated 2020 Jun 25. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory.)
   Google Scholar
• Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the approve trial. Lancet. 2008;372:1756–1764.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–1528.
   PubMed Web of Science ®Google Scholar
• Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ. 2004;171:1027–1028.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375:2519–2529.
   PubMed Web of Science ®Google Scholar
• Ng MKC, Celermajer DS. Glucocorticoid treatment and cardiovascular disease. Heart. 2004;90:829–830.
   PubMed Web of Science ®Google Scholar
• Wei L, MacDonald TM, Walker BR. Glucocorticoid medications and the risk for cardiovascular disease. Ann Intern Med. 2004;141:I–58.
   Google Scholar
• Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90:859–865.
   PubMed Web of Science ®Google Scholar
• Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764–770.
   PubMed Web of Science ®Google Scholar
• Yao T-C, Huang Y-W, Chang S-M, et al. Association between oral corticosteroid bursts and severe adverse events. Ann Intern Med. 2020;10.7326:M20-0432.
   PubMed Web of Science ®Google Scholar
• Noss MR, Saguil A. Gout: diagnosis and management. Am Fam Physician. 2017;96:668–670.
   PubMed Web of Science ®Google Scholar
• Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29–42.
   PubMed Web of Science ®Google Scholar
• Pascart T, Latourte A, Flipo R-M, et al. recommendations from the French Society of rheumatology for the management of gout: urate-lowering therapy. Joint Bone Spine. 2020;20:S1297–S319.
   Web of Science ®Google Scholar
• Araujo F, Cordeiro I, Teixeira F, et al. Portuguese recommendations for the diagnosis and management of gout. Acta Reumatol Port. 2014;39:158–171.
   PubMed Web of Science ®Google Scholar
• Yu K-H, Chen D-Y, Chen J-H, et al. Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan. Int J Rheum Dis. 2018;21:772–787.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Metabolism TG. Essence of the revised guideline for the management of hyperuricemia and gout. Japan Med Assoc J. 2012;55:324–329.
   PubMedGoogle Scholar